Article Versions Notes

Thaçi D, Singh D, Lee M, Timmis H, Jacobs D, Passier P, Rohrer S, Beetens J, Phung D, Sondag E, et al. Phase 1 and 2 Randomized Clinical Studies Determine Lack of Efficacy for Anti-IL-17C Antibody MOR106 in Moderate–Severe Atopic Dermatitis. Journal of Clinical Medicine. 2022; 11(23):7244. https://doi.org/10.3390/jcm11237244

Thaçi, Diamant, Dave Singh, Mark Lee, Helen Timmis, Dominique Jacobs, Paul Passier, Susanne Rohrer, Johan Beetens, De Phung, Eric Sondag, and et al. 2022. "Phase 1 and 2 Randomized Clinical Studies Determine Lack of Efficacy for Anti-IL-17C Antibody MOR106 in Moderate–Severe Atopic Dermatitis" Journal of Clinical Medicine 11, no. 23: 7244. https://doi.org/10.3390/jcm11237244

Thaçi, D., Singh, D., Lee, M., Timmis, H., Jacobs, D., Passier, P., Rohrer, S., Beetens, J., Phung, D., Sondag, E., Babic, G., Würth, G., Kloepfer, P., Härtle, S., & Hüttner, S. (2022). Phase 1 and 2 Randomized Clinical Studies Determine Lack of Efficacy for Anti-IL-17C Antibody MOR106 in Moderate–Severe Atopic Dermatitis. Journal of Clinical Medicine, 11(23), 7244. https://doi.org/10.3390/jcm11237244